Kelly R Bales

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi request reprint Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease
    Kelly R Bales
    Neuroscience Research Unit, Pfizer Global Research and Development, Groton, CT 06430, USA
    Neuropharmacology 59:295-302. 2010
  2. doi request reprint The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update
    Kelly R Bales
    Neuroscience Research Unit, Pfizer, Inc, Groton, CT 06340, USA
    Expert Opin Drug Discov 7:281-97. 2012
  3. doi request reprint Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice
    Kelly R Bales
    Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurosci 29:6771-9. 2009
  4. doi request reprint Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism
    Lingzhi Zhao
    Neuroscience Discovery Research and Integrative Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurosci 29:3603-12. 2009
  5. pmc Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody
    Kelly R Bales
    Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Invest 116:825-32. 2006
  6. ncbi request reprint Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides
    Milla Koistinaho
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Nat Med 10:719-26. 2004
  7. ncbi request reprint NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells
    Yansheng Du
    Department of Neurology, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Brain Res Mol Brain Res 136:177-88. 2005
  8. ncbi request reprint A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes
    Yu Liang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurochem 88:623-34. 2004
  9. ncbi request reprint Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice
    Jean Cosme Dodart
    Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Brain Res 955:191-9. 2002
  10. ncbi request reprint Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Alzheimer Res 4:179-84. 2007

Collaborators

Detail Information

Publications21

  1. doi request reprint Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease
    Kelly R Bales
    Neuroscience Research Unit, Pfizer Global Research and Development, Groton, CT 06430, USA
    Neuropharmacology 59:295-302. 2010
    ..Given the pivotal role apoE plays in maintaining neuronal membrane homeostasis, elevating the levels of apoE in brain may be a viable therapeutic strategy for the prevention and/or treatment of AD...
  2. doi request reprint The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update
    Kelly R Bales
    Neuroscience Research Unit, Pfizer, Inc, Groton, CT 06340, USA
    Expert Opin Drug Discov 7:281-97. 2012
    ..The largely overwhelmingly positive results obtained when testing potential clinical agents in these same animal models have failed to translate into similar positive clinical outcomes...
  3. doi request reprint Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice
    Kelly R Bales
    Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurosci 29:6771-9. 2009
    ..Therapeutic strategies aimed at increasing the soluble levels of apoE protein, regardless of isoform, may effectively prevent and (or) treat Alzheimer's disease...
  4. doi request reprint Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism
    Lingzhi Zhao
    Neuroscience Discovery Research and Integrative Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurosci 29:3603-12. 2009
    ....
  5. pmc Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody
    Kelly R Bales
    Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Invest 116:825-32. 2006
    ..Treatment with certain anti-A beta antibodies may therefore rapidly reverse this cholinergic dysfunction and relieve memory deficits associated with early AD...
  6. ncbi request reprint Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides
    Milla Koistinaho
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Nat Med 10:719-26. 2004
    ..Thus, Apoe seems to be important in the degradation and clearance of deposited Abeta species by astrocytes, a process that may be impaired in Alzheimer disease...
  7. ncbi request reprint NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells
    Yansheng Du
    Department of Neurology, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Brain Res Mol Brain Res 136:177-88. 2005
    ..Our data provide evidence that upregulation of APOE by A(beta) in astroglial cells is mediated by an NF-(kappa)B-element present in the 5'-flanking region of the APOE gene...
  8. ncbi request reprint A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes
    Yu Liang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurochem 88:623-34. 2004
    ..LXR/RXR agonists may have significant impact on the pathogenesis of multiple neurological diseases, including AD...
  9. ncbi request reprint Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice
    Jean Cosme Dodart
    Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Brain Res 955:191-9. 2002
    ..Taken together, these data support a role for apoE in APP processing in vivo...
  10. ncbi request reprint Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Alzheimer Res 4:179-84. 2007
    ..Taken together, these findings suggest that brain-penetrable LXR agonists or modulators may be useful therapeutic agents for the treatment and (or) prevention of Alzheimer's disease...
  11. ncbi request reprint ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo
    Ronald B DeMattos
    Neuroscience Discovery Research, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Neuron 41:193-202. 2004
    ..These findings demonstrate additive effects of apoE and clusterin on influencing Abeta deposition and that apoE plays an important role in regulating extracellular CNS Abeta metabolism independent of Abeta synthesis...
  12. ncbi request reprint Behavioral impairment of APP(V717F) mice in fear conditioning: is it only cognition?
    Robert Gerlai
    Lilly Research Laboratories, Neuroscience Department, Lilly Corporate Center, Drop Code 0510, Indianapolis, IN 46285, USA
    Behav Brain Res 136:503-9. 2002
    ....
  13. ncbi request reprint Immunotherapy for Alzheimer's disease: will vaccination work?
    Jean Cosme Dodart
    Lilly Research Laboratories, Eli Lilly and Company, Neuroscience Discovery Research, Indianapolis, IN 46285, USA
    Trends Mol Med 9:85-7. 2003
    ..However, given the potential efficacy of this approach, we believe that immunotherapy for AD should not be prematurely abandoned...
  14. ncbi request reprint Minocycline blocks bilirubin neurotoxicity and prevents hyperbilirubinemia-induced cerebellar hypoplasia in the Gunn rat
    Suizhen Lin
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Eur J Neurosci 22:21-7. 2005
    ..Our findings may lead to novel approaches for treating bilirubin-induced encephalopathy...
  15. ncbi request reprint Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model
    Jean Cosme Dodart
    Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Nat Neurosci 5:452-7. 2002
    ....
  16. ncbi request reprint Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta
    Margaret M Racke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurosci 25:629-36. 2005
    ..These results may have important implications for future immune-based therapeutic strategies for Alzheimer's disease...
  17. ncbi request reprint Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in aged Tg2576 mice
    Gary B Freeman
    Pfizer Worldwide Research and Development, Groton, CT 06340, USA
    Curr Alzheimer Res 9:1059-68. 2012
    ..In summary, intraperitoneal administration of a murine surrogate of ponezumab to aged Tg2576 mice for up to 6 months did not produce any compound-related brain microhemorrhage or other pathologies...
  18. doi request reprint Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators
    Martin Pettersson
    Neuroscience Medicinal Chemistry, Pfizer Worldwide Research and Development, Groton, CT 06340, USA
    Bioorg Med Chem Lett 22:2906-11. 2012
    ..Lead compounds such as 35 and 43 have moderate to good in vitro potency and excellent selectivity against Notch. Good oral bioavailability was achieved as well as robust brain Aβ42 lowering activity at 100 mg/kg po dose...
  19. ncbi request reprint Neurodegenerative disease research in the 21st century
    Kelly R Bales
    Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Drug Discov Today 9:553-6. 2004
  20. ncbi request reprint NF-kappaB mediates IL-1beta-induced synthesis/release of alpha2-macroglobulin in a human glial cell line
    Feng Gao
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
    Brain Res Mol Brain Res 105:108-14. 2002
    ..Our data suggest that attenuation of IL-1beta-induced alpha(2)M synthesis/release by blocking NF-kappaB activation may potentially be 'protective' against the development of late-onset AD...
  21. ncbi request reprint Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization
    Lihua Huang
    Bioproduct Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Anal Biochem 349:197-207. 2006
    ..Our data indicated that biantennary oligosaccharides lacking galactosylation had slightly faster clearance rates than other structures in the Fv domain...